Avantor, Inc. (AVTR) Shareholder Equity
- 2026-03-31: Treasury Stock, Common, ValueUSD $75.70M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-43.70M; Retained Earnings (Accumulated Deficit)USD $1.72B; Stockholders' Equity Attributable to ParentUSD $5.59B.
- 2025-12-31: Treasury Stock, Common, ValueUSD $75.70M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-16.90M; Retained Earnings (Accumulated Deficit)USD $1.67B; Stockholders' Equity Attributable to ParentUSD $5.57B.
- 2025-09-30: Treasury Stock, Common, ValueUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-23.60M; Retained Earnings (Accumulated Deficit)USD $1.62B; Stockholders' Equity Attributable to ParentUSD $5.57B.
- 2025-06-30: Treasury Stock, Common, ValueUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-10.40M; Retained Earnings (Accumulated Deficit)USD $2.33B; Stockholders' Equity Attributable to ParentUSD $6.29B.
Avantor, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD | Treasury Stock, Shares, Acquired shares | Common Stocks, Including Additional Paid in Capital USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $75.70M | $-43.70M | $1.72B | $5.59B | 6.60M | (m) | 3 month · $9.00M | (m) | (m) | $3.99B | (m) | (m) | (m) |
| 2025-12-31 | $75.70M | $-16.90M | $1.67B | $5.57B | 6.60M | 3 month · $75.00M 12 month · $75.70M | 12 month · $47.60M | (m) | 3 month · 6.60M | $3.98B | (m) | (m) | (m) |
| 2025-09-30 | (m) | $-23.60M | $1.62B | $5.57B | (m) | (m) | 3 month · $7.40M 9 month · $36.20M | (m) | (m) | $3.97B | (m) | (m) | (m) |
| 2025-06-30 | (m) | $-10.40M | $2.33B | $6.29B | (m) | (m) | 3 month · $15.80M 6 month · $28.80M | (m) | (m) | $3.96B | (m) | (m) | (m) |
| 2025-03-31 | (m) | $-117.70M | $2.27B | $6.10B | (m) | (m) | 3 month · $13.00M | (m) | (m) | $3.95B | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $-184.00M | $2.20B | $5.96B | 0.00 | (m) | 12 month · $47.00M | (m) | (m) | $3.94B | 12 month · $28.10M | (m) | (m) |
| 2024-09-30 | (m) | $-73.90M | $1.70B | $5.55B | (m) | (m) | 3 month · $11.30M 9 month · $35.30M | (m) | (m) | $3.92B | 3 month · $14.10M 9 month · $31.00M | (m) | (m) |
| 2024-06-30 | (m) | $-107.30M | $1.64B | $5.43B | (m) | (m) | 3 month · $11.60M 6 month · $24.00M | (m) | (m) | $3.90B | 3 month · $8.40M 6 month · $16.90M | (m) | (m) |
| 2024-03-31 | (m) | $-97.00M | $1.55B | $5.34B | (m) | (m) | 3 month · $12.40M | (m) | (m) | $3.88B | 3 month · $8.50M | (m) | (m) |
| 2023-12-31 | (m) | $-69.00M | $1.49B | $5.25B | (m) | (m) | 12 month · $40.20M | (m) | (m) | $3.83B | 12 month · $36.90M | (m) | (m) |
| 2023-09-30 | (m) | $-111.10M | $1.39B | $5.10B | (m) | (m) | 3 month · $9.70M 9 month · $31.60M | (m) | (m) | $3.82B | 3 month · $8.40M 9 month · $22.50M | (m) | (m) |
| 2023-06-30 | (m) | $-71.90M | $1.28B | $5.01B | (m) | (m) | 3 month · $9.30M 6 month · $21.90M | (m) | (m) | $3.80B | 3 month · $7.60M 6 month · $14.10M | (m) | (m) |
| 2023-03-31 | (m) | $-89.70M | $1.29B | $4.99B | (m) | (m) | 3 month · $12.60M | (m) | (m) | $3.79B | 3 month · $6.50M | (m) | (m) |
| 2022-12-31 | (m) | $-100.30M | $1.17B | $4.86B | (m) | (m) | 12 month · $49.10M | 12 month · $24.20M | (m) | $3.79B | 12 month · $8.40M | (m) | (m) |
| 2022-09-30 | (m) | $-211.80M | $1.03B | $4.59B | (m) | (m) | 3 month · $13.70M 9 month · $39.10M | 9 month · $24.20M | (m) | $3.77B | 3 month · $-100.00K 9 month · $1.30M | (m) | (m) |
| 2022-06-30 | (m) | $-148.30M | $861.70M | $4.47B | (m) | (m) | 3 month · $13.40M 6 month · $25.40M | 3 month · $8.10M 6 month · $24.20M | (m) | $3.76B | 3 month · $1.10M 6 month · $1.40M | (m) | (m) |
| 2022-03-31 | (m) | $-69.30M | $674.30M | $4.36B | (m) | (m) | 3 month · $12.00M | 3 month · $16.10M | (m) | $2.75B | 3 month · $300.00K | (m) | (m) |
| 2021-12-31 | (m) | $-43.20M | $483.90M | $4.20B | (m) | (m) | 12 month · $47.70M | 12 month · $64.60M | (m) | $2.75B | 12 month · $-3.60M | (m) | (m) |
| 2021-09-30 | (m) | $-38.10M | $389.90M | $4.10B | (m) | (m) | 3 month · $11.90M 9 month · $34.20M | 3 month · $16.10M 9 month · $48.40M | (m) | $2.75B | 3 month · $-900.00K 9 month · $-3.00M | (m) | (m) |
| 2021-06-30 | (m) | $1.40M | $233.10M | $2.99B | (m) | (m) | 3 month · $11.50M 6 month · $22.30M | 3 month · $16.20M 6 month · $32.30M | (m) | $1.75B | 3 month · $-1.30M 6 month · $-2.60M | (m) | (m) |
| 2021-03-31 | (m) | $-16.10M | $75.30M | $2.81B | (m) | (m) | 3 month · $10.80M | 3 month · $16.10M | (m) | $1.74B | 3 month · $-700.00K | (m) | (m) |
| 2020-12-31 | (m) | $21.70M | $-88.70M | $2.67B | (m) | (m) | 12 month · $42.20M | 12 month · $-64.60M | (m) | $1.74B | 12 month · $1.10M | (m) | (m) |
| 2020-09-30 | (m) | $-54.70M | $-140.30M | $2.55B | (m) | (m) | 3 month · $10.60M 9 month · $30.10M | 3 month · $16.10M 9 month · $48.40M | (m) | $1.74B | 3 month · $800.00K 9 month · $1.80M | (m) | (m) |
| 2020-06-30 | (m) | $-108.80M | $-98.10M | $2.54B | (m) | (m) | 3 month · $10.30M 6 month · $19.50M | 3 month · $16.20M 6 month · $32.30M | (m) | $1.74B | 3 month · $1.00M 6 month · $800.00K | (m) | (m) |
| 2020-03-31 | (m) | $-153.30M | $-158.30M | $2.44B | (m) | (m) | 3 month · $9.20M | 3 month · $16.10M | (m) | $1.75B | 3 month · $200.00K | (m) | (m) |
| 2019-12-31 | (m) | $-85.90M | $-203.70M | $2.46B | (m) | (m) | 12 month · $64.40M | 12 month · $-152.50M | (m) | $1.75B | 12 month · $1.50M | 12 month · $0.00 | 12 month · $-220.40M |
| 2019-09-30 | (m) | $-127.50M | $-274.30M | $2.36B | (m) | (m) | 3 month · $1.90M 9 month · $54.60M | 3 month · $16.40M 9 month · $136.40M | (m) | $1.75B | 3 month · $1.10M 9 month · $1.70M | (m) | 9 month · $220.40M |
| 2019-06-30 | (m) | $-64.70M | $-296.40M | $2.41B | (m) | (m) | 3 month · $48.70M 6 month · $52.70M | 3 month · $48.20M 6 month · $120.00M | (m) | $1.77B | 3 month · $100.00K 6 month · $600.00K | (m) | 3 month · $220.40M 6 month · $220.40M |
| 2019-03-31 | (m) | $-76.10M | (m) | $-3.14B | (m) | (m) | 3 month · $4.00M | 3 month · $71.80M | (m) | (m) | 3 month · $500.00K | (m) | (m) |
| 2018-12-31 | (m) | $-66.50M | $-238.40M | $-3.05B | (m) | (m) | 12 month · $13.00M | 12 month · $269.50M | (m) | $-2.75B | 12 month · $-400.00K | (m) | (m) |
| 2018-09-30 | (m) | $-33.10M | (m) | $-2.90B | (m) | (m) | 3 month · $4.10M 9 month · $10.30M | 3 month · $68.90M 9 month · $198.40M | (m) | (m) | 3 month · $800.00K 9 month · $1.70M | (m) | (m) |
| 2018-06-30 | (m) | $-31.50M | (m) | $-2.86B | (m) | (m) | 3 month · $2.30M 6 month · $6.20M | 3 month · $66.20M 6 month · $129.50M | (m) | (m) | 3 month · $300.00K 6 month · $900.00K | (m) | (m) |
| 2018-03-31 | (m) | $54.70M | (m) | $-2.69B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $26.40M | (m) | $-2.62B | (m) | (m) | 12 month · $31.80M | 12 month · $27.80M | (m) | (m) | 12 month · $3.10M | (m) | 12 month · $274.40M |
| 2016-12-31 | (m) | $-44.10M | (m) | $-510.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |